



B

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 09/546,573 Confirmation No.: 3408
Applicant : Mads HOLTEN-ANDERSEN, et al.
Filed : April 10, 2000
Title : TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES
TYPE-1 (TIMP-1) AS A CANCER MARKER
TC/Art Unit : 1643
Examiner: : S. L. Rawlings

Docket No. : 59866.000002
Customer No. : 21967

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBSTANCE OF TELEPHONE INTERVIEW UNDER 37 C.F.R. §1.133

Sir:

Applicants wish to summarize a telephone interview between Applicants' undersigned counsel and the Examiner, which took place on June 7, 2006.

Counsel contacted the Examiner to discuss the submission in the Third Supplemental Information Disclosure Statement ("Supplemental IDS") (filed on February 14, 2005) of Leroy *et al.*, a publication from the American Journal of Gastroenterology, 2004, Feb.; 99(2); 271-279. With the Supplemental IDS, Applicants submitted pages 271-276 of Leroy *et al.* because they did not have a complete copy thereof.

During the interview, Applicants acknowledged the receipt of a copy of Form PTO-1449 from the Supplemental IDS, initialed by the Examiner, and indicating that the Form was considered by the Examiner on May 21, 2005. The citation of Leroy *et al.* was crossed off in the copy of the Form. Applicants asked the Examiner what was meant by crossing off of the citation. The Examiner advised Applicants that his initials

next to the citation of Leroy *et al.* indicated that he considered the reference, but he crossed it off because a complete copy had not been submitted. Dr. Rawlings, the Examiner, advised that "crossing off" the identification of the reference on the Form meant that the reference would not be identified on the front page of the patent, but reiterated that the reference was considered.

Since at the time of the interview Applicants did not realize that, subsequently to February 14, 2005, they submitted a full copy of Leroy *et al.*, they inquired whether they could submit a supplemental IDS with a full copy thereof. Dr. Rawlings advised that he believed the rules did not provide for such submission at this juncture in the prosecution.

After the interview, Applicants realized that a full copy of Leroy *et al.* was submitted in an IDS filed on May 3, 2005, and subsequently considered by the Examiner on May 21, 2005. Thus, Applicants understand that the citation of Leroy *et al.* will be printed on the front page of the patent.


Based on the interview, Applicants also understand that any other citations which they have submitted in IDSs during prosecution of this application which were initialed by the Examiner but crossed off, were considered by the Examiner but will not be printed on the front page of the patent.

It is believed that no fees are due in connection with this filing. However, in the event that any fees are necessary, the Commissioner is hereby authorized to charge our Deposit Account No. 50-0206.

Appln. No.: 09/546,573
Substance of Telephone Interview
Under 37 C.F.R. §1.133, dated: June 9, 2006
Attorney Docket: 59866.000002

Respectfully submitted,

HUNTON & WILLIAMS LLP

A handwritten signature in black ink, appearing to read 'Stanislaus Aksman', is written over a horizontal line.

Stanislaus Aksman
Registration No. 28,562

Dated: June 9, 2005
Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

SA:sac